Sequoia staked its fate to the performance of Valeant Pharmaceuticals, a firm adored by
hedge fund managers and Sequoia — which plowed over a third of its portfolio into the stock — for its singular strategy: buy
small drug companies with
successful niche medicines, then skyrocket the price of those drugs.